The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network has significantly advanced efforts to stem the global HIV epidemic among pregnant women, infants, children and adolescents through the conduct of high-quality clinical trials. The IMPAACT vision and overall goal is to end the worldwide HIV epidemic among these vulnerable populations. To achieve this goal, IMPAACT will evaluate novel and durable treatments for both HIV and TB, to establish strategies for antiretroviral treatment (ART)-free remission, and to address the complications, co-morbidities, and co-infections affecting these HIV-infected and at-risk populations of interest. The results of our studies have contributed to licensure or labeling changes for new antiretrovirals/formulations for use in HIV-infected pregnant women, infants and children and influenced international and US guidelines for clinical care in these vulnerable populations. In addition to generating concrete evidence in these areas, IMPAACT's work has served to build much needed research and laboratory capacity in resource-limited settings, where burden of the HIV epidemic remains the greatest. The IMPAACT Laboratory Center has been integral to the Network's success in defining the standards of care for HIV infected pregnant women, children and adolescents. Many of the mechanistic underpinnings that explain the success of IMPAACT clinical trials are managed and discovered by IMPAACT Laboratory Center investigators. In this competitive renewal of the IMPAACT Laboratory Center, we propose a work closely the Operations Center and the Statistical and Data Management Center to develop, implement and evaluate the laboratory activities necessary to accomplish IMPAACT's research agenda. Further, the Laboratory Center will ensure that there are relevant state-of-the-art expertise and technologies and to oversee all laboratory operations confirming that all laboratory results are consistent, reproducible and can support study reconstruction.

Public Health Relevance

The Laboratory Center will provide laboratory-based scientific leadership, consultation and laboratory capacity, to enhance IMPAACT's Research Agenda and achieve its Scientific Aims. It will also provide the technical, regulatory and administrative infrastructure and oversight for all laboratory testing done in support of IMPAACT clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
2UM1AI106716-09
Application #
9986166
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Cleland, Naana G
Project Start
2014-01-01
Project End
2027-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
9
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Pediatrics
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Swindells, S; Gupta, A; Kim, S et al. (2018) Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003). Int J Tuberc Lung Dis 22:1016-1022
Rough, Kathryn; Seage 3rd, George R; Williams, Paige L et al. (2018) Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine. N Engl J Med 378:1593-1603
Gaufin, Thaidra; Tobin, Nicole H; Aldrovandi, Grace M (2018) The importance of the microbiome in pediatrics and pediatric infectious diseases. Curr Opin Pediatr 30:117-124
Eke, Ahizechukwu C; Chakhtoura, Nahida; Kashuba, Angela et al. (2018) Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum. J Acquir Immune Defic Syndr 78:308-313
Buchholz, Ursula J; Cunningham, Coleen K; Muresan, Petronella et al. (2018) Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children. J Infect Dis 217:1338-1346
Cranmer, Lisa M; Draper, Heather R; Mandalakas, Anna M et al. (2018) High Incidence of Tuberculosis Infection in HIV-exposed Children Exiting an Isoniazid Preventive Therapy Trial. Pediatr Infect Dis J 37:e254-e256
Walters, Elisabetta; Scott, Lesley; Nabeta, Pamela et al. (2018) Molecular Detection of Mycobacterium tuberculosis from Stools in Young Children by Use of a Novel Centrifugation-Free Processing Method. J Clin Microbiol 56:
McGuire, Erin P; Fong, Youyi; Toote, Christopher et al. (2018) HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine. J Virol 92:
Yeganeh, Nava; Watts, D Heather; Xu, Jiahong et al. (2018) Infectious Morbidity, Mortality and Nutrition in HIV-exposed, Uninfected, Formula-fed Infants: Results From the HPTN 040/PACTG 1043 Trial. Pediatr Infect Dis J 37:1271-1278
Chernoff, Miriam; Angelidou, Konstantia Nadia; Williams, Paige L et al. (2018) Assessing Psychiatric Symptoms in Youth Affected by HIV: Comparing a Brief Self-Administered Rating Scale with a Structured Diagnostic Interview. J Clin Psychol Med Settings 25:420-428

Showing the most recent 10 out of 122 publications